These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 12226532)
1. ApoE4: is it the absence of good or the presence of bad? Ashford JW J Alzheimers Dis; 2002 Jun; 4(3):141-3. PubMed ID: 12226532 [No Abstract] [Full Text] [Related]
2. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. Rebeck GW; Kindy M; LaDu MJ J Alzheimers Dis; 2002 Jun; 4(3):145-54. PubMed ID: 12226533 [No Abstract] [Full Text] [Related]
3. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. Hartman RE; Laurer H; Longhi L; Bales KR; Paul SM; McIntosh TK; Holtzman DM J Neurosci; 2002 Dec; 22(23):10083-7. PubMed ID: 12451108 [TBL] [Abstract][Full Text] [Related]
4. The presence of apoE4, not the absence of apoE3, contributes to AD pathology. Teter B; Raber J; Nathan B; Crutcher KA J Alzheimers Dis; 2002 Jun; 4(3):155-63. PubMed ID: 12226534 [No Abstract] [Full Text] [Related]
5. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. Buttini M; Yu GQ; Shockley K; Huang Y; Jones B; Masliah E; Mallory M; Yeo T; Longo FM; Mucke L J Neurosci; 2002 Dec; 22(24):10539-48. PubMed ID: 12486146 [TBL] [Abstract][Full Text] [Related]
6. APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice. Valencia-Olvera AC; Balu D; Moore A; Shah M; Ainis R; Xiang B; Saleh Y; Cai D; LaDu MJ; Tai LM J Alzheimers Dis; 2024; 97(4):1629-1639. PubMed ID: 38306049 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. Saunders AM J Neuropathol Exp Neurol; 2000 Sep; 59(9):751-8. PubMed ID: 11005255 [TBL] [Abstract][Full Text] [Related]
8. New piece in Alzheimer's puzzle. Travis J Science; 1993 Aug; 261(5123):828-9. PubMed ID: 8346434 [No Abstract] [Full Text] [Related]
9. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Ohm TG; Scharnagl H; März W; Bohl J Acta Neuropathol; 1999 Sep; 98(3):273-80. PubMed ID: 10483785 [TBL] [Abstract][Full Text] [Related]
10. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Strittmatter WJ; Weisgraber KH; Goedert M; Saunders AM; Huang D; Corder EH; Dong LM; Jakes R; Alberts MJ; Gilbert JR Exp Neurol; 1994 Feb; 125(2):163-71; discussion 172-4. PubMed ID: 8313935 [TBL] [Abstract][Full Text] [Related]
12. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340 [TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Kaplitt M; Gouras GK; Makimura H; Jovanovic J; Sweeney D; Greengard P; Relkin NR; Gandy S Ann N Y Acad Sci; 1996 Dec; 802():42-9. PubMed ID: 8993483 [No Abstract] [Full Text] [Related]
14. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Baum L; Chen L; Ng HK; Pang CP Microsc Res Tech; 2000 Aug; 50(4):278-81. PubMed ID: 10936880 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. Yang DS; Smith JD; Zhou Z; Gandy SE; Martins RN J Neurochem; 1997 Feb; 68(2):721-5. PubMed ID: 9003062 [TBL] [Abstract][Full Text] [Related]
16. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Strittmatter WJ; Weisgraber KH; Huang DY; Dong LM; Salvesen GS; Pericak-Vance M; Schmechel D; Saunders AM; Goldgaber D; Roses AD Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8098-102. PubMed ID: 8367470 [TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro. McGeer PL; Walker DG; Pitas RE; Mahley RW; McGeer EG Brain Res; 1997 Feb; 749(1):135-8. PubMed ID: 9070638 [TBL] [Abstract][Full Text] [Related]
18. APOE allele frequencies in demented and nondemented elderly Jamaicans. Morgan OS; Eldemire DA; Thesiger CH; Luseko J; Sahota A; Gao S; Hall KS; Hendrie HC Ann Neurol; 1998 Apr; 43(4):545. PubMed ID: 9546341 [No Abstract] [Full Text] [Related]
19. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Strittmatter WJ; Saunders AM; Schmechel D; Pericak-Vance M; Enghild J; Salvesen GS; Roses AD Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1977-81. PubMed ID: 8446617 [TBL] [Abstract][Full Text] [Related]
20. Isoform-specific proteolysis of apolipoprotein-E in the brain. Elliott DA; Tsoi K; Holinkova S; Chan SL; Kim WS; Halliday GM; Rye KA; Garner B Neurobiol Aging; 2011 Feb; 32(2):257-71. PubMed ID: 19278755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]